



Short Communication

Received: August 18, 2009 Accepted: September 5, 2009

Study of *In Vitro* and *In Vivo* Extraction of Kavalactones of Pharmaceutical Form Containing Ground Plant Drug (Piper methysticum G. Forster)

Willian RICHARDES COSTA 1, Lucas ROSSI SARTORI 1 & José C. TAVARES CARVALHO 2*

¹ Laboratório de Fitofármacos, Universidade de Alfenas, Rod. MG 179, km 0, CP 23, CEP 37130-000, Alfenas, Minas Gerais, Brazil ² Laboratório de Pesquisa em Fármacos, Universidade Federal do Amapá, Rod. JK, km 2, CEP 68902-380, Macapá, Amapá, Brasil

SUMMARY. An evaluation of the extraction of pharmacological markers (kavalactones) of the plant species Piper methysticum (kava-kava) was conducted. Capsules containing ground kava-kava were submitted to an in vitro method using a controlled dissolution system where the extractive mediums were a solution of 0.1M HCl, phosphate buffered solution (pH = 6.8) and distilled water, at 30 and 60 min, and in vivo that was based on the pylorus ligation method in rats. In the in vitro system starting from 6 capsules (3 g) containing the kava-kava powder, the following extractive concentrations of kavalactones were obtained: HCl (30 min.) = 0.93% (27.9 mg), HCl (60 min.) = 1.1% (33 mg), buff. (30 min) = 2.8% (84 mg), buff. (60 min.) = 0.7% (21 mg), water (30 min.) = 0.71% (21.3 mg) and water (60 min.) = 2.6% (78 mg), while in the *in vivo* method, $\overline{1}$ and 2 h after administration of $\overline{500}$ mg of the kava-kava powder through gavage, the extractive concentrations of total kavalactones were: 1h = 1.31% (6.55 mg) and 2h = 1.41%(7.05 mg). In the in vitro system a slight difference was observed among the solutions, which were not statistically significant, and the same occurred with the in vivo experiment, although at the time of 2 h after administration it proved more effective in the extraction of kavalactones by the gastric juice, but below the dose recommended for therapeutic use.

KEY WORDS: Ground plant drug, Kavalactones, Piper methysticum,

289 ISSN 0326-2383

Author to whom correspondence should be addressed. E-mail: farmacos@unifap.br